|
Xilio Therapeutics, Inc. (XLO) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Xilio Therapeutics, Inc. (XLO) Bundle
Looking to determine the intrinsic value of Xilio Therapeutics, Inc.? Our XLO DCF Calculator integrates real-world data with comprehensive customization features, allowing you to adjust forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -53.5 | -73.7 | -85.6 | -73.8 | -58.0 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| EBITDA, % | 100 | 100 | 100 | 100 | -914.27 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | 1.1 | 1.5 | 1.8 | 1.9 | 1.6 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 |
| Depreciation, % | 100 | 100 | 100 | 100 | 25.91 | 85.18 | 85.18 | 85.18 | 85.18 | 85.18 |
| EBIT | -54.6 | -75.2 | -87.4 | -75.7 | -59.6 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| EBIT, % | 100 | 100 | 100 | 100 | -940.18 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 19.2 | 198.1 | 120.4 | 44.7 | 55.3 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | 5.1 | 5.1 | 5.1 | 5.1 | 5.1 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 5.1 | 5.1 | 5.1 | 5.1 | 5.1 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 5.4 | 3.1 | 3.1 | 1.1 | 2.6 | 5.6 | 5.6 | 5.6 | 5.6 | 5.6 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 40.57 | 88.11 | 88.11 | 88.11 | 88.11 | 88.11 |
| Capital Expenditure | -2.2 | -1.1 | -1.9 | -.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -0.56747 | -0.11349 | -0.11349 | -0.11349 | -0.11349 | -0.11349 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -54.6 | -73.7 | -86.5 | -75.7 | -59.6 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -50.2 | -75.6 | -86.5 | -76.4 | -56.5 | 2.0 | 9.2 | 9.2 | 9.2 | 9.2 |
| WACC, % | 4.93 | 4.91 | 4.92 | 4.93 | 4.93 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 33.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 9 | |||||||||
| Terminal Value | 320 | |||||||||
| Present Terminal Value | 252 | |||||||||
| Enterprise Value | 285 | |||||||||
| Net Debt | -47 | |||||||||
| Equity Value | 332 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | 6.21 |
What You Will Get
- Real XLO Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Xilio Therapeutics' future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Xilio Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Watch Xilio Therapeutics’ intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Xilio Therapeutics, Inc.'s (XLO) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for Xilio Therapeutics, Inc. (XLO)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Variables: Easily adjust inputs to suit your financial modeling needs.
- Real-Time Feedback: Monitor immediate changes to Xilio’s valuation as you modify data points.
- Pre-Configured Data: Comes with Xilio’s latest financial metrics for swift assessments.
- Relied Upon by Experts: Utilized by financial analysts and investors for strategic decision-making.
Who Should Use This Product?
- Investors: Accurately assess Xilio Therapeutics, Inc.'s (XLO) fair value to inform investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Acquire knowledge of financial modeling techniques employed by leading biotech firms.
- Educators: Implement it as a resource for teaching valuation practices in finance courses.
What the Template Contains
- Historical Data: Includes Xilio Therapeutics, Inc.'s (XLO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Xilio Therapeutics, Inc.'s (XLO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Xilio Therapeutics, Inc.'s (XLO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.